Lexicon to Present at JPMorgan Healthcare Conference

The Woodlands, TX -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has announced that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the JPMorgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California on Thursday, January 10, 2008 at 9:30 a.m. Pacific Time. Dr. Sands will provide an overview of Lexicon's clinical and preclinical development programs and corporate objectives.

A live webcast of Lexicon's presentation may be accessed on its corporate Web site. An archived version of the webcast will be available on the website through January 18, 2008.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has development programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, and autoimmune diseases. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit the company's Web site.